The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the manufacturer.

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™

Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode Identifier.

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation ap | The company said its U.

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real-time brain activity to improve Parkinson disease symptom control without manual adjustments.

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive technology personalizing treatment of Parkinson’s symptoms using advanced stimulation deep in the brain.

Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment for people with Parkinson's disease, a major milestone for the technology.